Hollywood Media Changes Name and Stock Symbol to Novel Stem International Corp. and “NSTM” to Reflect Focus on Stem Cell-Based Diagnostics to Better Select Cancer Chemotherapies
Boca Raton, FL and Jerusalem, Israel, September 25, 2018 – Hollywood Media Corp. (OTC
Pink: HOLL) announced today it has changed its corporate name to NovelStem International
Corp. and that its common stock will commence trading under a new OTC Pink symbol
“NSTM” and new CUSIP number 67001V109, effective September 26, 2018.
The NovelStem International name reflects the Company’s strategic transformation through a
July 2018 acquisition of an initial 20% stake in Jerusalem, Israel-based NewStem Ltd. (view
acquisition press release). The Company is now focused on NewStem’s novel stem cell-based
diagnostic technology and has the right to increase its NewStem ownership up to 33% based on
the completion of up to $2 million in follow-on contributions.
NewStem has developed diagnostic technology that can predict patients’ resistance to
chemotherapy to allow for better, targeted cancer treatments with the potential to reduce incidents
of chemotherapy resistance. Drug resistance is a major cause of treatment failure in cancer
chemotherapy, and currently it is only recognized after the first course of treatment has been
completed. NewStem’s diagnostic solutions are based on the research of human haploid
pluripotent stem cells by Chief Science Officer Professor Nissim Benvenisty of the Azrieli Center
for Stem Cells and Genetic Research at The Hebrew University of Jerusalem. NewStem’s
technology enables informed, personalized selection of chemotherapy treatments for cancer
About NovelStem International Corp.
NovelStem is focused on the substantial commercial potential of NewStem Ltd.’s novel stem-cellbased
diagnostic technology, which can predict patients’ resistance to chemotherapy to allow for
better, targeted cancer treatments with the potential to reduce incidents of chemotherapy
resistance. NovelStem has a 20% stake in NewStem and the right to increase its ownership up to
33% based on the completion of up to $2 million in follow-on contributions over the next 18
months. NovelStem has 35.4 million common shares outstanding.
NewStem is a spinoff of Yissum, The Hebrew University of Jerusalem’s technology-transfer
company led by CEO Ayelet Dilion-Mashiah. NewStem’s diagnostic solutions are based on the
research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty of
the Azrieli Center for Stem Cells and Genetic Research. NewStem holds the intellectual property,
reagents and experience required for hHPSC isolation, differentiation, genetic manipulation,
immunogenicity and tumorigenicity.
NovelStem also owns a 50% interest in Netco Partners, a joint venture that owns the Net Force
publishing franchise, which delves into the thrilling and fast-paced worlds of digital crimes,
espionage and crypto-currencies. NovelStem is working to relaunch Net Force by seeking a new
publishing agreement that would target the release of the first new book starting in 2019.
NovelStem Investor Relations:
Bill Jones or David Collins – Catalyst IR